Additional shares added to the initial offering of 4.0MM. See the link below to look over the filing.
siliconinvestor.com
THE OFFERING
Common stock offered.......... 4,900,000 shares
Common stock to be outstanding
after this offering......... 45,741,297 shares
Use of proceeds............... To fund the further clinical development and
commercialization of Angiomax; to fund research
and development of clevidipine; to provide
working capital; and for general corporate
purposes. See "Use of Proceeds."
Nasdaq National Market
symbol........................ MDCO
The foregoing information is based on the number of shares outstanding as
of February 28, 2003.
This number does not take into account:
- 4,884,752 shares of common stock reserved for issuance pursuant to
outstanding stock options at a weighted average exercise price of $11.87
per share;
- 1,688,600 shares of common stock reserved for future awards under our
stock plans; and
- 1,092,895 shares of common stock reserved for issuance pursuant to
outstanding common stock purchase warrants at an exercise price of $5.92
per share.
In addition, except as otherwise noted, all information in this prospectus
assumes no exercise of the underwriters' over-allotment option.
The price movement in the stock has been interesting. Especially Friday. We will have to see what happens as we move to Friday next week.
Mike |
